Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Eli Lilly and Company
Age
18–85
Sex
ALL
Healthy volunteers
Accepted
You may be eligible if
(Part A)
Gradual and progressive changes in memory function reported by participants or their partners for greater than or equal to (≥) 6 months at screening, and a clinical diagnosis of mild cognitive impairment due to AD, or AD dementia, as determined by the investigator or based upon medical history
Mini-Mental State Examination score ≥16
Have clinical laboratory test results within normal reference range or results with acceptable deviations that are judged to be not clinically significant by the investigator
Have a study partner who will provide written informed consent to participate, is in frequent contact with the participant (defined as at least 10 hours per week), and will accompany the participant to study visits or be available through telephone at designated times
(Part B)
overtly healthy males or females
have a body mass index of 18.0 to 32.0 kg/m2, inclusive
To qualify as a participant of the first-generation Japanese origin, the participant, the participant's biological parents, and all of the participant's biological grandparents must be of exclusive Japanese descent and born in Japan.
You may not be if
(Part A)
Have history or presence of uncontrolled asthma, significant autoimmune disease, hereditary angioedema, or known history of common variable immune deficiency
Contraindication to positron emission tomography (PET)
Have a history or presence of serious or unstable illnesses including cardiovascular, hepatic, renal, gastrointestinal, respiratory, endocrine, psychiatric, immunologic, or hematologic disease and other conditions that, in the investigator's opinion, could interfere with the analyses in this study, or increase risk for study intervention administration, or result in a participant's life expectancy of less than (\<)24 months
Have received treatment with biologic agents (such as monoclonal antibodies, including marketed drugs) within 3 months or 5 half-lives (whichever is longer) prior to dosing
Have had significant medical history of dizziness, syncope, or vasovagal attacks within the past 3 years
Contraindication to magnetic resonance imaging (MRI), including claustrophobia that cannot be managed with low-dose sedatives or the presence of contraindicated metal (ferromagnetic) implants/cardiac pacemaker
(Part B)
have a family history of early onset AD (AD diagnosed prior to 65 years of age)
have used or intend to use over-the-counter or prescription medication including herbal medications within 14 days prior to dosing.
have a history or presence of significant psychiatric disorders
have an abnormal blood pressure and/or pulse rate as determined by the investigator, or a pre-existing history of hypertension
any clinically significant ECG or brain MRI abnormalities
Clareo Health | A Study of LY3372993 in Participants With Alzheimer's Disease (AD) and Healthy Participants
